[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346022-105":59,"doc-detail-346022-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","exploring-the-role-of-cd155-in-urothelial-carcinoma-of-the-urinary-bladder-an-immunohistochemical-study-its-correlation-with-pd-l1","Exploring the Role of CD155 in Urothelial Carcinoma of the Urinary Bladder - An Immunohistochemical Study & Its Correlation With PD-L1","","This research article investigates CD155 expression in urinary bladder urothelial carcinoma and examines its relationship with clinicopathological features and PD-L1. Immunohistochemical staining was performed on 67 cases to assess CD155 and PD-L1 positivity. CD155 showed positivity in 41.8% of cases and correlated with invasive tumors and advanced T stage, while PD-L1 positivity (35.8%) associated with advanced T stage, distant metastasis, muscle invasion, and lymphovascular emboli. A significant positive correlation was observed between CD155 and PD-L1, supporting combined therapeutic blockade potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/exploring-the-role-of-cd155-in-urothelial-carcinoma-of-the-urinary-bladder-an-immunohistochemical-study-its-correlation-with-pd-l1/346022/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/exploring-the-role-of-cd155-in-urothelial-carcinoma-of-the-urinary-bladder-an-immunohistochemical-study-its-correlation-with-pd-l1/346022.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of evaluating CD155 in urothelial carcinoma?","Question",{"text":112,"@type":113},"The study aimed to evaluate CD155 expression in urinary bladder urothelial carcinoma using immunohistochemistry and correlate it with clinicopathological parameters and PD-L1 expression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were CD155 and PD-L1 measured in the study?",{"text":117,"@type":113},"CD155 and PD-L1 were assessed by immunohistochemical staining on 67 cases of urinary bladder urothelial carcinoma.",{"name":119,"@type":110,"acceptedAnswer":120},"What correlations were found between CD155, PD-L1, and disease severity?",{"text":121,"@type":113},"CD155 positivity (41.8%) was significantly associated with invasive tumors and advanced T stage, while PD-L1 positivity (35.8%) correlated with advanced T stage, distant metastasis, muscle invasion, and lymphovascular emboli. CD155 and PD-L1 expression also showed a statistically significant positive correlation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346022,1790093728,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","RESEARCH ARTICLE  \n\n| Editorial Proc | ess: Submission:07/26/2025 Acceptance:02/03/2026 Published:02/06/2026 |\n| --- | --- |\n\nExploring the Role of CD155 in Urothelial Carcinoma of the Urinary Bladder: An Immunohistochemical Study & Its Correlation With PD-L1  \nPassant Essam Shibel1, Aya Magdy Elyamany1 *, Galal El Shorbagy2, Eman Ahmed Abd Elmaogod3  \nAbstract  \nBackground: Urinary bladder carcinoma is one of the most immunogenic cancers. Several immune checkpoint inhibitors targeting programmed death-ligand 1 (PD-L1) have been approved by the FDA for bladder carcinoma treatment. However, additional immunotherapeutic targets are still needed. CD155 is another immune checkpoint molecule that has been shown to be overexpressed in several cancers and is associated with poor prognosis. Aim: This study aimed to evaluate CD155 expression in cases of urinary bladder urothelial carcinoma using immunohistochemistry and to correlate this expression with the clinicopathological parameters of the cases as well as with PD-L1 expression. Methods: Immunohistochemical staining for CD155 and PD-L1 was performed on 67 cases of urothelial carcinoma of the urinary bladder. Results: CD155 was positive in 41.8% of cases and was significantly associated with invasive tumors and advanced T stage. PD-L1 was positive in 35.8% of cases and was significantly associated with advanced T stage, distant metastasis, muscle invasion and lymphovascular emboli. A statistically significant positive correlation was observed between the expression of both CD155 and PD-L1 . Conclusion: Our study demonstrated increased expression of CD155 in urothelial carcinoma of the urinary bladder with advancing stage, suggesting its potential as a therapeutic target. Additionally, CD155 expression correlated positively with PD-L1 expression, indicating that some patients might benefit from a combined blockade of both targets.  \nKeywords: Urinary bladder – Urothelial carcinoma – CD155 – PD-L1 – Immunohistochemistry  \nAsian Pac J Cancer Prev, 27 (2), 667-675  \nIntroduction  \nWorldwide, bladder cancer (BC) ranks as the tenth most common cancer [1]. In Egypt, urinary bladder cancer is the most prevalent cancer in males (16%) and the second most common cancer in females (12%), leading to more than 7900 deaths per year, which is considerably higher than most other parts of the world [2] .  \nRadical cystectomy (RC) with pelvic lymph node dissection is indicated for patients with muscle-invasive BC and those with Bacillus Calmette-Guerin (BCG)-resistant non-muscle invasive BC [3] . Unfortunately, up to 40% of patients experience lymph node or distant metastases within five years post-operative [4]. For a better prognosis, maintenance chemotherapy has been considered [5], however; not all patients respond well to such anti-cancer drugs; additionally, treatment-related adverse events were recorded [6] .  \nNowadays, immunotherapies have been introduced into the treatment of various cancers including bladder  \ncarcinoma. Bladder urothelial carcinoma is known tobe highly immunogenic, where it shows one of the highest mutational burdens among different cancers and is characterized by relatively high PD-L1 expression. Immunotherapy by intravesical BCG has been used in superficial bladder carcinoma treatment for decades. Lately, two PD-1 targeting antibodies (nivolumab and pembrolizumab) and three PD-L1 targeting antibodies (avelumab, atezolizumab, and durvalumab) have been FDA approved for treatment of metastatic urinary bladder carcinoma [7] .  \nDespite such advances, obstacles regarding resistance to immune checkpoint inhibitors (ICIs), whether primary or acquired, appeared. Thus, additional targets are needed while considering the possibility of ICI combination therapy to attain synergetic effects with improved clinical outcomes [8] .  \nCluster of differentiation 155 (CD155) is atransmembrane protein, initially described as a poliovirus receptor (PVR) . It functions as a ligand for three  ","cbCais5JnZlMAxgd","https://ap.wps.com/l/cbCais5JnZlMAxgd","pdf",1000295,"English","# Abstract\n# Introduction\n## Background and clinical need\n## Immunotherapy and checkpoint resistance\n## CD155 immune roles and rationale for study\n# Methods and results\n## Immunohistochemical assessment\n## CD155 and PD-L1 associations","[{\"question\":\"What was the main objective of evaluating CD155 in urothelial carcinoma?\",\"answer\":\"The study aimed to evaluate CD155 expression in urinary bladder urothelial carcinoma using immunohistochemistry and correlate it with clinicopathological parameters and PD-L1 expression.\"},{\"question\":\"How were CD155 and PD-L1 measured in the study?\",\"answer\":\"CD155 and PD-L1 were assessed by immunohistochemical staining on 67 cases of urinary bladder urothelial carcinoma.\"},{\"question\":\"What correlations were found between CD155, PD-L1, and disease severity?\",\"answer\":\"CD155 positivity (41.8%) was significantly associated with invasive tumors and advanced T stage, while PD-L1 positivity (35.8%) correlated with advanced T stage, distant metastasis, muscle invasion, and lymphovascular emboli. CD155 and PD-L1 expression also showed a statistically significant positive correlation.\"}]","Exploring the Role of CD155 in Urothelial Carcinoma of the Urinary Bladder - An Immunohistochemical Study & Its Correlation With PD-L1 | PDF",1790059709,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9cafec5c5ab8b429d96b6ba19d54a86.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c68310941fe5539df8fdfab254458b4.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/362a6574c78fcdb83263124eaeeb1ae5.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b75facd89f0730c10dfb413689ee2b71.webp",980,1385]